Valanbio Therapeutics
Raleigh, US · Founded 2015 · Delaware corporation
Founders & leadership
CD
Clayton DuncanNamed on SEC filing
PZ
Pei ZhouNamed on SEC filing
MA
Moise A. KhayrallahNamed on SEC filing
EJ
Eric J. TooneNamed on SEC filing
SH
Sam HopkinsNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$421K disclosed across 1 round · 2018
▶$421KraisedJan 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$421KraisedJan 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Clayton DuncanExecutive Officer, Director
- Pei ZhouExecutive Officer, Director
- Moise A. KhayrallahExecutive Officer, Director
- Eric J. TooneDirector
- Sam HopkinsDirector
- Offering amount
- $600K
- Amount sold
- $421K
- Minimum investment
- $7K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Valanbio Therapeutics raised?
- Valanbio Therapeutics has disclosed $421K raised across 1 round.
- Where is Valanbio Therapeutics headquartered?
- Valanbio Therapeutics is headquartered in Raleigh, US.